As part of the agreement, Ranbaxy along with its partners Cipher Pharm and Galephar Pharma, has entered into a non-exclusive license agreement with Actavis under the Dublin-headquartered company may start selling its generic version of Absorica in the US on 27 December 2020 (nine months before the expiration of the patents in September 2021) or earlier under certain circumstances, Sun Pharma said.
top of page
Search
Recent Posts
See AllGeneral Motors has secured an Indian patent on a hybrid powertrain control system for vehicles. The patent rights are currently assigned...
Taking into consideration the Delhi High court’s order staying the abandonment orders passed by the Trademarks Office, the Registrar of...
The order of the Delhi High Court allows the Competition Commission of India (CCI) to attend to complaints on abuse of dominance of...
bottom of page
Commenti